Back to Search
Start Over
Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC).
- Source :
- Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p9128-9128, 1p
- Publication Year :
- 2023
Details
- Language :
- English
- ISSN :
- 0732183X
- Volume :
- 41
- Database :
- Supplemental Index
- Journal :
- Journal of Clinical Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 164015158
- Full Text :
- https://doi.org/10.1200/JCO.2023.41.16_suppl.9128